Development and Characterization of Imatinib Mesylate Liposome: For In-vitro Anti-Cancer Activity

Abstract

According to our research, liposomes loaded with imatinib mesylate were formulated using a rotary evaporator and the thin film hydration method. FTIR, DSC, and XRD studies were carried out to ensure that the drug excipients in the final formulation were compatible. The improved liposome batch (F7) was tested for particle size (353.9 nm), zeta potential (- 46.0 mV), drug release (92.8%), and entrapment efficiency (94.29%) after 72 hours. Studies using TEM have shown that imatinib mesylate-loaded liposomes have a spherical form. Finally, in-vitro anticancer activity was assessed through the MTT assay, which revealed an IC50 value of 0.2959μg mL-1 for treating Human leukaemia monocytic cell lines. The process was refined based on data concerning the rotary evaporator speed, solvent system ratio and volume, hydration media pH, manufacturing yield, entrapment efficiency, in-vitro release, and improved in vitro anti-cancer activity.